Lenalidomide With Rituximab Shows Activity on Refractory CLL

Share this content:
Lenalidomide with rituximab exhibited activity patients with relapsed/refractory CLL.
Lenalidomide with rituximab exhibited activity patients with relapsed/refractory CLL.

In combination with lenalidomide, rituximab exhibited activity and acceptable toxicity profile for heavily pretreated patients with relapsed/refractory chronic lymphocytic leukemia (CLL), according to a study published in the journal Leukemia Research.1

For this phase 2 trial, investigators enrolled 25 patients ranging from 41 to 79 years. All participants received lenalidomide 2.5 mg orally on days 1 to 7, 5 mg on days 8 to 14, and 10 mg on days 15 to 21, followed by 7 days without treatment. For subsequent cycles, patients received lenalidomide at a dose of 20 mg daily on days 1 to 21.

Rituximab was given at an intravenous dose of 375 mg/m2 weekly on day 15 for 4 doses of each 28-day cycle. Treatment was given until disease progression or unacceptable toxicity.

The overall response rate was 45.8%, and 61.1% among evaluable patients; all responses were partial responses. Median time to treatment failure was 14.3 months; median overall survival had not yet been reached.

RELATED: Rituximab Maintenance Therapy Promising for Patients With Pre-treated CLL

The most common grade 3 to 4 treatment-related adverse event was neutropenia, which was observed in nearly 75% of patients. The most frequently reported nonhematologic toxicity was infection (29%).


  1. Chavez JC, Piris-Villaespesa M, Dalia S, et al. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leuk Res. 2016;47:78-83.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs